Literature DB >> 23792959

Crystal structure of a human IκB kinase β asymmetric dimer.

Shenping Liu1, Yohann R Misquitta, Andrea Olland, Mark A Johnson, Kerry S Kelleher, Ron Kriz, Laura L Lin, Mark Stahl, Lidia Mosyak.   

Abstract

Phosphorylation of inhibitor of nuclear transcription factor κB (IκB) by IκB kinase (IKK) triggers the degradation of IκB and migration of cytoplasmic κB to the nucleus where it promotes the transcription of its target genes. Activation of IKK is achieved by phosphorylation of its main subunit, IKKβ, at the activation loop sites. Here, we report the 2.8 Å resolution crystal structure of human IKKβ (hIKKβ), which is partially phosphorylated and bound to the staurosporine analog K252a. The hIKKβ protomer adopts a trimodular structure that closely resembles that from Xenopus laevis (xIKKβ): an N-terminal kinase domain (KD), a central ubiquitin-like domain (ULD), and a C-terminal scaffold/dimerization domain (SDD). Although hIKKβ and xIKKβ utilize a similar dimerization mode, their overall geometries are distinct. In contrast to the structure resembling closed shears reported previously for xIKKβ, hIKKβ exists as an open asymmetric dimer in which the two KDs are further apart, with one in an active and the other in an inactive conformation. Dimer interactions are limited to the C-terminal six-helix bundle that acts as a hinge between the two subunits. The observed domain movements in the structures of IKKβ may represent trans-phosphorylation steps that accompany IKKβ activation.

Entities:  

Keywords:  Crystallography; Enzyme Mechanisms; NF-kappa B (NF-KB); Signaling; Threonine-Serine Protein Kinase

Mesh:

Substances:

Year:  2013        PMID: 23792959      PMCID: PMC3829360          DOI: 10.1074/jbc.M113.482596

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

2.  IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.

Authors:  J D Woronicz; X Gao; Z Cao; M Rothe; D V Goeddel
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

3.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.

Authors:  F Mercurio; H Zhu; B W Murray; A Shevchenko; B L Bennett; J Li; D B Young; M Barbosa; M Mann; A Manning; A Rao
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

Review 4.  Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models.

Authors:  S Gerondakis; R Grumont; R Gugasyan; L Wong; I Isomura; W Ho; A Banerjee
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

5.  BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice.

Authors:  James R Burke; Mark A Pattoli; Kurt R Gregor; Patrick J Brassil; John F MacMaster; Kim W McIntyre; Xiaoxia Yang; Violetta S Iotzova; Wendy Clarke; Joann Strnad; Yuping Qiu; F Christopher Zusi
Journal:  J Biol Chem       Date:  2002-10-25       Impact factor: 5.157

6.  Mechanistic link between PKR dimerization, autophosphorylation, and eIF2alpha substrate recognition.

Authors:  Madhusudan Dey; Chune Cao; Arvin C Dar; Tomohiko Tamura; Keiko Ozato; Frank Sicheri; Thomas E Dever
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

7.  NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176.

Authors:  L Ling; Z Cao; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  Functional dissection of the TBK1 molecular network.

Authors:  Adriana Goncalves; Tilmann Bürckstümmer; Evelyn Dixit; Ruth Scheicher; Maria W Górna; Evren Karayel; Cristina Sugar; Alexey Stukalov; Tiina Berg; Robert Kralovics; Melanie Planyavsky; Keiryn L Bennett; Jacques Colinge; Giulio Superti-Furga
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  38 in total

1.  RELA haploinsufficiency in CD4 lymphoproliferative disease with autoimmune cytopenias.

Authors:  William A Comrie; Aiman J Faruqi; Susan Price; Yu Zhang; V Koneti Rao; Helen C Su; Michael J Lenardo
Journal:  J Allergy Clin Immunol       Date:  2018-01-02       Impact factor: 10.793

2.  Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.

Authors:  José García-Rodríguez; Santiago Pérez-Rodríguez; María A Ortiz; Raquel Pereira; Angel R de Lera; F Javier Piedrafita
Journal:  Bioorg Med Chem       Date:  2014-01-10       Impact factor: 3.641

3.  MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells.

Authors:  Venumadhav Janganati; Jessica Ponder; Meenakshisundaram Balasubramaniam; Poornima Bhat-Nakshatri; Eli E Bar; Harikrishna Nakshatri; Craig T Jordan; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2018-08-10       Impact factor: 6.514

4.  Succinamide derivatives of melampomagnolide B and their anti-cancer activities.

Authors:  Venumadhav Janganati; Jessica Ponder; Shraddha Thakkar; Craig T Jordan; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2017-05-08       Impact factor: 3.641

5.  Crosstalk between the Akt/mTORC1 and NF-κB signaling pathways promotes hypoxia-induced pulmonary hypertension by increasing DPP4 expression in PASMCs.

Authors:  Ying Li; Li Yang; Liang Dong; Zhi-Wei Yang; Jing Zhang; Sheng-Li Zhang; Meng-Jie Niu; Jing-Wen Xia; Yi Gong; Ning Zhu; Xiu-Juan Zhang; Yuan-Yuan Zhang; Xiao-Min Wei; You-Zhi Zhang; Peng Zhang; Sheng-Qing Li
Journal:  Acta Pharmacol Sin       Date:  2019-07-17       Impact factor: 6.150

6.  Effects of ALS-associated TANK binding kinase 1 mutations on protein-protein interactions and kinase activity.

Authors:  Junqiang Ye; Jonah Cheung; Valeria Gerbino; Göran Ahlsén; Christina Zimanyi; David Hirsh; Tom Maniatis
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-20       Impact factor: 11.205

7.  Structurally plastic NEMO and oligomerization prone IKK2 subunits define the behavior of human IKK2:NEMO complexes in solution.

Authors:  Myung Soo Ko; Tapan Biswas; Maria Carmen Mulero; Andrey A Bobkov; Gourisankar Ghosh; Tom Huxford
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-08-25       Impact factor: 3.036

8.  IκB kinase β (IKBKB) mutations in lymphomas that constitutively activate canonical nuclear factor κB (NFκB) signaling.

Authors:  Xin Kai; Vasant Chellappa; Carlos Donado; Deepak Reyon; Yurie Sekigami; Dalya Ataca; Abner Louissaint; Hamid Mattoo; J Keith Joung; Shiv Pillai
Journal:  J Biol Chem       Date:  2014-08-08       Impact factor: 5.157

Review 9.  Therapeutic potential of IKK-β inhibitors from natural phenolics for inflammation in cardiovascular diseases.

Authors:  Peng Zhou; Fang Hua; Xiang Wang; Jin-Ling Huang
Journal:  Inflammopharmacology       Date:  2020-01-01       Impact factor: 4.473

10.  A novel allosteric inhibitor that prevents IKKβ activation.

Authors:  Hongbo Liu; Hao Liang; Hu Meng; Xiaobing Deng; Xiaoling Zhang; Luhua Lai
Journal:  Medchemcomm       Date:  2018-01-09       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.